Celgene Corp ( CELG - Nasdaq )

[alingtonsky]

06/10/13 - 01:03 PM ED
...
As of noon trading, Celgene Corporation (CELG) is down $1.40 (-1.2%) to $119.01 on light volume Thus far, 1.1 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.2 million shares. The stock has ranged in price between $118.18-$121.00 after having opened the day at $120.91 as compared to the previous trading day's close of $120.41.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Celgene Corporation has a market cap of $48.2 billion and is part of the health care sector. The company has a P/E ratio of 35.1, above the S&P 500 P/E ratio of 17.7. Shares are up 47.3% year to date as of the close of trading on Friday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
...

BIIB Stock | 5 Drugs Stocks Dragging The Industry Down - TheStreet

 

[alingtonsky]

07/11/13 - 08:32 AM EDT

Celgene (CELG ) reported positive results Thursday from a large phase III study seeking to establish the company's multiple myeloma drug as the preferred treatment for newly diagnosed patients.

The so-called MM-020 study achieved its primary endpoint demonstrating that treatment with a combination of Revlimid plus low-dose dexamethasone significantly delayed the time before patients' cancer returned compared to treatment with a three-drug chemotherapy regimen known as MPT, Celgene said.

Details from the MM-020 study were not released Thursday but will be presented at the American Society of Hematology annual meeting in December.

Based on results from the MM-020 study, Celgene plans to submit regulatory filings in Europe and the U.S. seeking to expand Revlimid's label to include treatment for newly diagnosed multiple myeloma patients, the company said.

...

Celgene Front-Line Revlimid Study Succeeds - TheStreet

 

[alingtonsky]

By Zacks Equity Research
43 minutes ago
Celgene Corporation (CELG) reported first quarter 2014 adjusted earnings of $1.46 per share, beating the year-ago earnings by approximately 17%. Higher revenues drove earnings in the reported quarter. The Zacks Consensus Estimate was $1.43 per share.

Quarter in Details

Total revenues climbed 18% to $1.73 billion in the first quarter of 2014. Revenues were boosted by the impressive performance of cancer drugs, Revlimid and Abraxane. Net product sales climbed 19% to $1.71 billion. Revenues were short of the Zacks Consensus Estimate of $1.77 billion.

Net sales of Revlimid, the key growth driver at Celgene, came in at $1.14 billion, reflecting an increase of 14% over the year-ago period. The drug did well both in the U.S. (up 13%) and international markets (up 16%).

Market share gains, geographic expansion and increased duration of therapy drove sales in the first quarter of 2014. The drug is approved in many countries across the globe in combination with dexamethasone for treating multiple myeloma (MM) patients, who have received at least one prior therapy. Revlimid is also approved in the U.S. in the relapsed refractory mantle cell lymphoma indication.

Revlimid is also available in many countries for treating transfusion-dependent anemia due to low or intermediate-1-risk myelodysplastic syndrome MDS) associated with a deletion 5q cytogenetic abnormality (with or without additional cytogenetic irregularities). Celgene is looking to expand the drug’s label. To attain the objective, it has filed regulatory applications in the U.S. and EU in the newly diagnosed MM indication. Regulatory actions are expected next year.

Net sales of another cancer drug, Abraxane, jumped 50.6% to $184.8 million. The drug did well both in the U.S. (up 51% to $141.5 million) and international markets (up 49.3% to $43.3 million). Sales in the U.S. were boosted by the label expansion of the drug into the non-small cell lung cancer indication in the final quarter of 2012 and the pancreatic cancer indication in Sep 2013. The drug is off to a strong start in the EU for the pancreatic cancer indication (approval gained in Jan 2014).

Net sales of Vidaza declined 27% to $148 million. Soft U.S. sales (down 83%) due to generic competition hurt results during the quarter. U.S. sales of Pomalyst, approved by the U.S. Food and Drug Administration FDA) in Feb 2013 in combination with low-dose dexamethasone for the treatment of relapsed and refractory multiple myeloma patients, who have received at least two prior therapies, came in at $89 million in the first quarter of 2014, flat sequentially.

The approval of the drug (trade name: Imnovid) in the EU was gained in Aug 2013. Sales of the drug in international markets were $47 million in the first quarter of 2014 as opposed to $32 million in the preceding quarter.

All other product sales (inclusive of Thalomid, Istodax and an authorized generic version of Vidaza in the U.S.) came in at $95 million in the first quarter of 2014, up 33.8%.

Research and development (R&D) expenses (excluding stock-based compensation and other special items) climbed 8.5% to $358 million. The increase was due to Celgene’s efforts to develop its pipeline. Selling, general and administrative expenses (excluding stock-based compensation and other special items) in the quarter increased 25.5% to $418 million.

Costs associated with the launches of Abraxane in the pancreatic cancer indication, Pomalyst/Imnovid led to the rise in SG&A expenses. Costs associated with the anticipated launch of apremilast (proposed brand name: Otezla) also pushed up SG&A costs.

Outlook for 2014 Maintained

Celgene re-affirmed the guidance provided by it on Jan 13, 2014. Total revenues in 2014 are projected to increase 15% year over year to $7.5 billion driven by strong product sales. Net product sales are still expected to grow 16% in 2014 to $7.3–$7.4 billion.

Revlimid is expected to be the major contributor with 2014 sales in the range of $4.9–$5.0 billion, up 16%. Abraxane net sales are projected in the range of $850 million–$900 million, up 35%. Celgene expects 2014 earnings (excluding stock-based compensation and other special items) in the range of $7.0–$7.20 per share. The Zacks Consensus Estimate for 2014 hints at earnings of $6.34 per share on revenues of $7.6 billion.

Celgene Inks Deal

Celgene also announced that it has inked a deal with the privately-held Irish company Nogra Pharma Ltd. for the development and subsequent commercialization of GED-0301, for the treatment of moderate-to-severe Crohn’s disease and other indications. The candidate has completed phase II studies for treating Crohn’s disease.

Celgene intends to initiate a phase III registration program on the candidate by Dec 31, 2014. According to the deal, Celgene will pay the private entity an upfront payment of $710 million in addition to milestone payments. Furthermore, Celgene will pay Nogra royalties (tiered) on sales of the drug following approval. The deal is aimed at strengthening Celgene’s already strong pipeline.

We note Celgene has been constantly inking deals to bolster its pipeline. Late last year, Celgene inked a deal with OncoMed Pharmaceuticals, Inc. (OMED) for the joint development and commercialization of up to six anti-cancer stem cell candidates from OncoMed's biologics pipeline.

Celgene carries a Zacks Rank #3 (Hold). ...

http://finance.yahoo.com/news/celgene-earnings-grow-over-q1-162939232.html


Dizionario Italiano-Inglese - WordReference.com

 

[alingtonsky]

June 2, 2016 3:09 pm EDT
...

A new study from IMS Health has projected that the global market for cancer treatments rose to $107 billion in 2015. While the cost of this is said to be driven by a record level of innovation, the projected costs are set to skyrocket. IMS Health is projecting that annual growth in the oncology drug market is expected to be 7.5% to 10.5% through 2020, which puts the drug market’s future value at a whopping $150 billion.

IMS showed that over 20 tumor types are being treated with one or more of the 70 new cancer treatments that have been launched in the past five years. Many of these drugs are not even yet available to patients in most countries.

That figure of $107 billion for 2015 was an increase of 11.5% on a constant-dollar basis versus 2014. This measurement is using ex-manufacturer prices, but it also does not reflect off-invoice discounts or other rebates and patient access programs.

There may be at least more hints of negotiated health care costs here. IMS noted that payers are expected to tighten their negotiation stance with manufacturers, and that they will adopt new payment models to drive greater value.

Additional data points from the study are as follows:

• The pipeline of oncology drugs in clinical development has expanded by more than 60 percent during the past decade, with almost 90 percent of the focus on targeted agents.
• The median time from patent filing to approval for oncology drugs in 2015 was 9.5 years, down from 10.3 years in 2013.
• In the past three years, three molecules were approved within four years of patent registration.
• The overwhelming majority of drugs are available in the U.S., Germany, UK, Italy, France and Canada.
• Of the drugs approved in 2014 and 2015 by a set of developed countries analyzed, only the U.S., France and Scotland have more than half included on reimbursement lists at the end of 2015.
• The annual growth rate in cancer drug costs has risen from 3.8 percent in 2011 to 11.5 percent in 2015.
• The U.S. now accounts for about 45 percent of the global total market for therapeutics, up from 39 percent in 2011 (due in part from a stronger U.S. dollar and more rapid adoption of newer therapies).
• Cancer drugs now make up 11.5 percent of total drug costs, up from 10.5 percent in 2011, in the United States.
• Net price growth in the U.S. on existing branded oncology drugs have averaged an estimated 4.8 percent in 2015, compared with 6.4 percent invoice price growth.
• Cancer drugs dispensed in the United States through retail channels now account for more than one-third of total costs, up from 25 percent ten years ago.
• Average total treatment costs in the U.S. for patients in commercial insurance plans with a cancer diagnosis who are receiving active treatment reached $58,000 in 2014, up 19 percent from 2013.
• Patients with commercial insurance who were treated in 2014 with cancer drugs received by injection or infusion were responsible for more than $7,000 of costs on average, compared to $3,000 for those patients receiving only oral medicines.

This report was effectively released right before the key ASCO conference this weekend.

By Jon C. Ogg

How the Cancer Drug Market Will Rise to $150 Billion by 2020